The EVOLVE-MI (EVOLocumab Very Early After Myocardial Infarction) trial (NCT05284747) aims to evaluate the impact of PCSK9 inhibition on clinical outcomes following an ACS. Here, PCSK9 is linked to myocardial infarction.